HIV Prevention

Senate testimony on FY25 appropriations for HIV and hepatitis programs

Our nation can eliminate both HIV and viral hepatitis, but without investing additional resources to accelerate our efforts, we will continue to fall short of these ambitious goals. Increased investment–and certainly not cuts–in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact.

read more

Comments to MD Prescription Drug Affordability Board on HIV treatments

While we are supportive of the Maryland Prescription Drug Affordability Board (PDAB) goal of improving treatment affordability, we urge PDAB members and staff to address concerns surrounding access to provider-recommended HIV treatments at the individual level and the impact on broader public health goals and provide clarity around the affordability review process to enable meaningful community input.

read more

House testimony on FY25 appropriations for HIV and hepatitis programs

Our nation can eliminate both HIV and viral hepatitis, but without an infusion of new resources to accelerate our efforts, we will continue to fall short of these ambitious goals. While we realize strict spending caps are in place, increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both these potentially deadly infectious diseases.

read more

Support for Rhode Island’s H 8041 “An Act Relating to Insurance—Prescription Drug Benefits”

We voice our strong support for Rhode Island’s H 8041 (“An Act Relating to Insurance—Prescription Drug Benefits”) which stipulates that, when calculating an enrollee’s overall contribution to any out-of-pocket maximum or any cost-sharing requirement under a health plan, an insurer or pharmacy benefit manager shall include any amounts paid by the enrollee or paid on behalf of the enrollee by another person. We thank you for considering this legislation and are pleased to offer our support.

read more

Pin It on Pinterest